News | Thrombectomy Devices | February 12, 2019

JETi Thrombectomy System Safe and Effective for Deep Vein Thrombosis

Study presented at CIRSE 2018 demonstrated efficacy in single-session setting without post-procedural lytic infusion

JETi Thrombectomy System Safe and Effective for Deep Vein Thrombosis

February 12, 2019 — A study presented at the 2018 annual meeting of the Cardiovascular and Interventional Radiology Society of Europe (CIRSE) explored the safety and efficacy of the JETI-8 Peripheral Thrombectomy System for the treatment of acute deep vein thrombosis (DVT). The study, presented by Jean Cournoyer-Rodrigue, M.D., CHUM Research Center, Montreal, showed 83 percent technical success.

The JETi Thrombectomy System is a device that breaks-up and removes thrombus from the coronary and peripheral vasculature, incorporating a powerful internal jet technology that macerates thrombus just inside its mouth and lubricates the proximally flowing aspirate. The device has a desirable safety profile, allows for single-session treatment potential with or without lytics, has U.S. Food and Drug Administration (FDA) 510K clearance and CE Mark.

Jeti was tested in 23 venous thromboembolism (VTE) procedures, resulting in 83 percent technical success, defined as restoration of integrate flow with the elimination of any obstructing lesion, without overnight CDT. In addition, 4 out of 23 procedures required post-procedure lytic infusion before achieving procedural and technical success, with overnight CDT. Current thrombectomy market leaders such as Angiojet have only demonstrated single-session success of 34 percent in their seminal Pearl registry, according to Walk Vascular. No complication, hemolysis or blood transfusion was reported. Mean thrombus removal across all patients was 93 percent.

For more information: www.cirse.org


Related Content

News | Cardiovascular Clinical Studies

September 28, 2023 — Merck announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review a ...

Home September 28, 2023
Home
News | Cardiovascular Clinical Studies

September 19, 2023 — A mathematical and computational model of the human heart entirely developed at Politecnico di ...

Home September 19, 2023
Home
News | Cardiovascular Clinical Studies

September 18, 2023 — Pregnant women with a history of substance abuse face a dramatically increased risk of death from ...

Home September 18, 2023
Home
News | Cardiovascular Clinical Studies

September 18, 2023 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & ...

Home September 18, 2023
Home
News | Cardiovascular Clinical Studies

September 18, 2023 — Anthos Therapeutics, Inc., a clinical stage company developing innovative therapies for ...

Home September 18, 2023
Home
News | Cardiovascular Clinical Studies

September 14, 2023 — Myocardial infarction, the number one cause of sudden death in adults and the number two cause of ...

Home September 14, 2023
Home
News | Cardiovascular Clinical Studies

September 12, 2023 — Mineralys Therapeutics, Inc. has presented final results from the Target-HTN Phase 2 trial of ...

Home September 12, 2023
Home
News | Cardiovascular Clinical Studies

September 12, 2023 — Merck announced new analyses from studies of sotatercept, Merck’s novel investigational activin ...

Home September 12, 2023
Home
News | Cardiovascular Clinical Studies

September 8, 2023 — Imbria Pharmaceuticals, Inc., a clinical stage, cardiometabolic company dedicated to developing ...

Home September 08, 2023
Home
Subscribe Now